ArticlePathology international2026
Prevalence and Independence of p53 Signatures and β-Catenin Signatures in Risk-Reducing Salpingo-Oophorectomy Specimens.
Article in Pathology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Clusters of epithelial cells of the fallopian tube exhibiting aberrant p53 expression, termed "p53 signatures," are detected at a relatively high frequency and have been regarded as putative precursors of high-grade serous carcinoma (HGSC). In contrast, the recently proposed "β-catenin signature" represents a distinct tubal epithelial alteration characterized by the aberrant expression of β-catenin, the biological significance of which remains unclear. To clarify the frequency and spatial relationship between the two lesions, we analyzed 30 consecutive risk-reducing salpingo-oophorectomy specimens from BRCA1/2 mutation carriers using the sectioning and extensively examining the fimbriated end protocol and performed immunohistochemical evaluation for p53, β-catenin, and Ki-67. p53 signatures and β-catenin signatures were each identified in seven cases (23%). Two cases (6.7%) harbored both lesions; however, no spatial overlap or histological continuity was observed. Neither lesion demonstrated significant associations with BRCA mutation subtype, age, body mass index, or parity. Furthermore, no cases showed serous tubal intraepithelial lesion, serous tubal intraepithelial carcinoma, or HGSC. These findings suggest that p53 signatures and β-catenin signatures may represent distinct localized epithelial alterations in the fallopian tube, although further molecular and spatial analyses are required to clarify their biological relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.